Related Experiment Video
Updated: Oct 12, 2025
Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells
Published on: June 9, 2020
Effects of Iodonium Analogs on Nadph Oxidase 1 in Human Colon Cancer Cells
Krishnendu K Roy1, Jiamo Lu2, James H Doroshow1,2
1Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Abstract:
Recent studies suggest that of the molecules postulated to function as inhibitors of the NADPH oxidase family of enzymes iodonium analogs known to broadly interfere with flavin dehydrogenase function demonstrate mechanistic validity as NADPH oxidase poisons. In recent work, we have produced a series of novel iodonium compounds as putative inhibitors of these oxidases. To evaluate the potential utility of two novel molecules with favorable chemical properties, NSC 740104 and NSC 751140, we compared effects of these compounds to the two standard inhibitors of this class, diphenyleneiodonium and di-2-thienyliodonium, with respect to antiproliferative, cell cycle, and gene expression effects in human colon cancer cells that require the function of NADPH oxidase 1. Both new agents blocked NADPH oxidase-related reactive oxygen production, inhibited tumor cell proliferation, produced a G1/S block in cell cycle progression, and inhibited NADPH oxidase 1 expression at the mRNA and protein levels at low nM concentrations in a fashion similar to or better than the parent molecules. These studies suggest that NSC 740104 and NSC 751140 should be developed further as mechanistic tools to better understand the role of NADPH oxidase inhibition as an approach to the development of novel therapeutic agents for colon cancer.
Insights
Novel iodonium compounds, NSC 740104 and NSC 751140, effectively inhibit NADPH oxidase 1 in colon cancer cells, blocking proliferation and impacting cell cycle and gene expression. These agents show promise for developing new colon cancer therapies.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- NADPH oxidase enzymes are implicated in various cellular processes, including cancer.
- Iodonium analogs are known inhibitors of flavin dehydrogenase function and potential NADPH oxidase poisons.
- Novel compounds are needed to explore NADPH oxidase inhibition as a therapeutic strategy.
Purpose of the Study:
- To evaluate two novel iodonium compounds, NSC 740104 and NSC 751140, as potential inhibitors of NADPH oxidase 1.
- To compare the efficacy of these novel compounds with standard inhibitors (diphenyleneiodonium and di-2-thienyliodonium).
- To assess the antiproliferative, cell cycle, and gene expression effects in human colon cancer cells.
Main Methods:
- Synthesis of novel iodonium compounds (NSC 740104 and NSC 751140).
- Treatment of human colon cancer cells with novel and standard iodonium compounds.
- Assays for reactive oxygen species production, cell proliferation, cell cycle progression, and NADPH oxidase 1 mRNA and protein levels.
Main Results:
- Both NSC 740104 and NSC 751140 effectively blocked NADPH oxidase-related reactive oxygen production.
- The novel compounds inhibited colon tumor cell proliferation and induced a G1/S cell cycle block.
- NADPH oxidase 1 expression was inhibited at both mRNA and protein levels at low nanomolar concentrations.
Conclusions:
- NSC 740104 and NSC 751140 demonstrate potent inhibition of NADPH oxidase 1 in colon cancer cells.
- These compounds exhibit antiproliferative and cell cycle-arresting effects, similar to or better than existing inhibitors.
- Further development of NSC 740104 and NSC 751140 is warranted for understanding NADPH oxidase inhibition in colon cancer therapy.
More Related Videos
04:53Detection of Total Reactive Oxygen Species in Adherent Cells by 2',7'-Dichlorodihydrofluorescein Diacetate Staining
Published on: June 23, 2020
09:31Analyzing Oxidative Stress in Murine Intestinal Organoids using Reactive Oxygen Species-Sensitive Fluorogenic Probe
Published on: September 17, 2021
